Johnson & Johnson (NYSE:JNJ) Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 26.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 41,453 shares of the company's stock after selling 14,613 shares during the period. Johnson & Johnson comprises about 0.6% of Sunbelt Securities Inc.'s portfolio, making the stock its 29th largest holding. Sunbelt Securities Inc.'s holdings in Johnson & Johnson were worth $6,875,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Tallon Kerry Patrick purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $290,000. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC lifted its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Allegiance Financial Group Advisory Services LLC lifted its holdings in shares of Johnson & Johnson by 8.4% in the fourth quarter. Allegiance Financial Group Advisory Services LLC now owns 3,329 shares of the company's stock valued at $481,000 after purchasing an additional 258 shares in the last quarter. Finally, Schnieders Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 4.6% in the fourth quarter. Schnieders Capital Management LLC now owns 70,725 shares of the company's stock valued at $10,228,000 after purchasing an additional 3,120 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.3%

NYSE JNJ opened at $152.44 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a 50-day simple moving average of $153.75 and a 200 day simple moving average of $153.81. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market cap of $366.78 billion, a PE ratio of 16.96, a PEG ratio of 2.31 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.41%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analysts Set New Price Targets

Several brokerages recently issued reports on JNJ. Royal Bank Of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Raymond James Financial cut their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Finally, Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.